Cytosorbents Corp Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Cytosorbents Corporation on July 19, 2023. The filing discloses the entry into a material definitive agreement regarding the appointment of a new Chief Financial Officer.
Key Financial Metrics
The filing text does not provide revenue, profit, cash flow, margins, debt, or liquidity metrics. This report focuses exclusively on executive compensation and employment terms.
Material Changes and Executive Appointment
On July 19, 2023, the Company announced the appointment of Alexander D'Amico as Chief Financial Officer, effective August 7, 2023. The Employment Agreement includes the following compensation terms:
- Base Salary: $425,000 annually.
- Cash Bonus: Eligible for up to 45% of base salary contingent on milestones and performance.
- Signing Bonus: $5,000 cash.
- Contract Term: Initial term through December 31, 2025, with automatic one-year renewals unless notice of non-renewal is provided.
Equity Awards and Contingencies
Mr. D'Amico received the following equity awards, subject to specific vesting schedules and a contingent settlement structure:
| Award Type | Quantity | Vesting Conditions |
|---|---|---|
| Annual ISOs | 70,000 | 25,000 at 6 months; 15,000 at 1st, 2nd, and 3rd anniversaries. |
| Annual RSUs | 45,000 | 50% at 1st anniversary; 50% at 2nd anniversary. |
| Change in Control RSUs | 150,000 | Vest only upon a Change in Control. |
| Performance ISOs | 215,000 | Vest upon achievement of 2022-2025 performance pool milestones. |
| Signing RSUs | 15,000 | Cliff vest at 2nd anniversary or upon Change in Control. |
Contingent Settlement Note: The Annual RSUs, Change in Control RSUs, and Signing RSUs are awarded on a contingent basis. They will be subject to cash settlement unless the Company receives shareholder approval to amend its Long-Term Incentive Plan to increase available shares sufficient for non-cash settlement prior to the settlement date.
Outlook and Risks
The filing does not contain forward-looking guidance, management commentary on financial outlook, or specific risk factors beyond the standard definitions of "Cause," "Good Reason," and "Change of Control" within the employment agreement. The primary contingency risk relates to the potential cash settlement of equity awards if shareholder approval for share plan amendments is not obtained.
Investor Verification Checklist
- Verify the effective start date of the new CFO (August 7, 2023) and the departure date of the previous CFO, if applicable.
- Confirm the status of shareholder approval required to convert contingent equity awards from cash settlement to stock issuance.
- Review the specific milestones defined in the 2022-2025 performance pool for the 215,000 Performance ISOs.
- Assess the impact of the new compensation structure on future stock-based expense recognition.